Clinical analysis of modified voriconazole regimen on prevention of invasive mycosis in patients with myeloid neoplasms
刘聪,李国辉,陈任安,秦炜炜,黄斯勇,周柰岑,郭怀鹏,严学倩,及月茹,陈怡,刘利
DOI: https://doi.org/10.3760/cma.j.cn511693-20201224-00263
2022-01-01
Abstract:Objective:To explore the effect of modified voriconazole regimen on the plasma concentration of voriconazole, the prevention of invasive fungal diseases and treatment cost in patients with myeloid neoplasms.Methods:From January 2018 to March 2020, a total of 108 patients with myeloid neoplasms who were admitted to the Department of Hematology of Tangdu Hospital affiliated the Air Force Military Medical University, Xi′an International Medical Center Hospital, and Shaanxi Provincial Cancer Hospital were selected as the research subjects. All patients planed to have treatment of modified voriconazole regimen to prevent the IFD. For adult patients, the loading dose of voriconazole was 6 mg/(kg·times), and the maintenance dose was 200 mg/time, with an interval of 12 h in modified voriconazole regimen. For patients aged 12-18 years old plus weight ≥50 kg, the dose of voriconazole was the same as that for adult patients. For patients aged <12 years old or aged 12-18 years old plus weight <50 kg, the loading dose of voriconazole was 6 mg/(kg·times), the maintenance dose of voriconazole was 4 mg/(kg·times), with an interval of 12 h. The trough plasma concentration of voriconazole was measured, and the compliance rate of plasma concentration was calculated. Analysis of variance or t test was used to compare the trough plasma concentrations of voriconazole in different types of patients. The χ2 test or Fisher exact probability method were used to compare the breakthrough rate of fungal infection and the incidence of adverse reactions in different types of patients. According to previous research results and clinical experience, a multivariate unconditional logistic regression analysis was performed on the related factors that may affect the efficacy of voriconazole in preventing IFD. This study was approved by the Medical Ethics Committee of Tangdu Hospital (Approval: No. 201709-11), and all patients signed an informed consent form for clinical research. Results:① In patients with modified voriconazole regimen, the trough plasma concentration of voriconazole was (1.89 ±1.21) mg/L, of which 89% patients (96/108) were ≥ 0.5 mg/L and 78% (84/108) patients were ≥1 mg/L. Taking 1 mg/L as the threshold of voriconazole trough plasma concentration, the compliance rate of trough plasma concentration of patients with daily doses <5 mg/(kg·d) was lower than that of ≥ 5 mg/(kg·d) [59% (10/17) vs 81% (74/91)], the difference was statistically significant ( χ2=4.194, P=0.041). ② The trough plasma concentration of voriconazole in patients with different ages was significantly different ( F=11.102, P=0.001). The trough plasma concentration of voriconazole in patients with daily dose <5 mg/(kg·d) was lower than that of ≥ 5 mg/(kg·d)[(1.35±0.79) mg/L vs (2.06±0.57) mg/L], the difference was statistically significant ( t=2.763, P=0.042). ③ Among 108 patients in this study, 9 patients (8.3%, including 1 clinically diagnosed patient and 8 suspected patients) developed IFD.The trough plasma concentration of voriconazole in patients with IFD was lower than that of non-IFD patients [(1.08±0.80) mg/L vs (2.11±1.21 mg/L)] with statistical difference ( t=3.85, P<0.001). The breakthrough rates of fungal infection in patients with voriconazole trough plasma concentration ≤0.5 mg/L and >0.5 mg/L were 33.3% (4/12) and 5.2% (5/96), respectively, which in patients with ≤1 mg/L and >1 mg/L were 25.0% (6/24) and 3.6% (3/84), respectively, and the differences were statistically significant ( P=0.001, 0.001). According to previous research results and clinical experience, a multivariate unconditional logistic regression analysis was performed on age, voriconazole trough plasma concentration, primary disease, and neutropenia time. The results showed that the higher the voriconazole trough plasma concentration was, the better the IFD preventive effect of patients would get ( OR=3.584, 95% CI: 1.690-7.601, P=0.001). ④ The incidence of hallucinations in patients with voriconazole trough plasma concentration ≤4 mg/L (10/101, 10.9%) was significantly lower than that in patients >4 mg/L (3/7, 42.9%), and the difference was statistically significant ( P=0.045). ⑤ The average daily treatment cost of the modified voriconazole regimen was (653.89±44.69) yuan, which was lower than the (991.52±188.05) yuan which calculated according to the recommended dose in the drug insert ( t=18.157, P<0.001). Conclusions:The modified voriconazole regimen did not reduce trough plasma concentration in patients with myeloid neoplasms, and had better preventive effect and fewer adverse reactions. Meanwhile it can significantly reduced the treatment cost of antifungal.